In a patient receiving testosterone replacement therapy who develops erythrocytosis, what can cause decreased serum iron levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Decreased Serum Iron Levels in Testosterone-Induced Erythrocytosis

In patients receiving testosterone replacement therapy who develop erythrocytosis, decreased serum iron levels are caused by increased iron utilization for accelerated red blood cell production, mediated by testosterone's suppression of hepcidin—the master iron regulatory hormone.

Mechanism of Iron Depletion

Testosterone triggers a cascade of changes in iron metabolism that directly depletes serum iron stores:

  • Hepcidin suppression: Testosterone markedly suppresses serum hepcidin within 1 week of administration in a dose-dependent manner 1. This suppression is more pronounced in older men and corresponds to greater rises in hemoglobin 1.

  • Increased iron mobilization and utilization: The suppression of hepcidin allows increased iron absorption and mobilization from stores, but this iron is rapidly consumed by accelerated erythropoiesis 2. Soluble transferrin receptor (sTR) levels and the sTR/log ferritin ratio increase significantly, indicating heightened iron utilization for red blood cell production 2.

  • Depletion of iron stores: Testosterone administration reduces serum ferritin by 32% within 3 months without altering total iron, transferrin, or transferrin saturation initially 3. This reflects the consumption of iron stores to support the increased erythropoietic demand.

Clinical Implications

The iron depletion occurs because testosterone simultaneously stimulates erythropoietin (EPO) production while suppressing hepcidin, creating a mismatch where iron demand for red blood cell production exceeds available supply 2. At 1 and 3 months of therapy, EPO levels rise significantly while ferritin and hepcidin levels decrease 2. By 6 months, EPO levels return toward baseline but remain nonsuppressed despite elevated hemoglobin, suggesting establishment of a new EPO/hemoglobin set point 2.

Critical Caveat About Iron Deficiency

In iron-deficient patients, testosterone paradoxically worsens anemia despite stimulating erythropoiesis 4. Testosterone treatment in iron-deficient mice reduced red cell count and caused ineffective erythropoiesis with increased early-to-late erythroblast ratios and elevated serum LDH, suggesting erythropoietin resistance associated with iron deficiency 4. This underscores that adequate iron stores are essential for testosterone's erythropoietic effects.

Monitoring Recommendations

The FDA label mandates that hemoglobin and hematocrit levels should be checked periodically to detect polycythemia in patients receiving long-term androgen administration 5. The 2018 Endocrine Society guidelines specify that clinicians should evaluate men who develop erythrocytosis and withhold testosterone therapy until hematocrit returns to normal range, then resume at a lower dose 6. Therapeutic phlebotomy is mentioned as effective for managing testosterone-induced erythrocytosis 6, though recent evidence questions whether phlebotomy-induced iron depletion might paradoxically increase thrombotic risk by lowering tissue oxygen and depleting iron stores 7.

The key clinical takeaway: decreased serum iron in testosterone-treated patients with erythrocytosis reflects functional iron deficiency from accelerated consumption, not true iron deficiency, and requires careful assessment before implementing phlebotomy or iron supplementation.

References

Research

The role of iron in mediating testosterone's effects on erythropoiesis in mice.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2020

Guideline

testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.